Market Size of Fabry Disease Treatment Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 6.80 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Fabry Disease Treatment Market Analysis
The Fabry disease treatment market is expected to register a CAGR of 6.8% over the forecast period.
COVID-19 significantly impacted the Fabry disease treatment market since Fabry disease patients receiving treatment in the hospitals experienced delayed drug infusion or disruptions in drug infusion services provided by the healthcare staff during the early pandemic period. Also, the COVID-19-infected Fabry disease patients witnessed changes in their immune system functions. For instance, according to the article published in June 2022 in PubMed, in Fabry Disease (FD) patients, the risk for severe COVID-19 was driven by the immune system rather than by FD itself. Thus, the complication of FD was exacerbated due to COVID-19; however, the unavailability of immediate medication significantly impacted the market growth. Besides, the market is expected to witness significant growth in the coming years owing to the rise in advancements in FD treatment and strong pipeline assets by the key market players.
The factor contributing to the market's growth includes a surge in awareness associated with Fabry disease treatment, a rise in R&D related to Fabry disease, and promising pipeline products, which drives the market's growth. Awareness associated with Fabry's disease is crucial for patients and healthcare staff. In recent years, there has been a rise in awareness related to treating Fabry disease in different countries such as the United States, United Kingdom, and others. For instance, according to the National Fabry Disease Foundation (NFDF), 'April' is observed as Fabry Disease Awareness Month annually in the United States. The awareness programs include educating the public, patients, caregivers, and healthcare professionals. Furthermore, the awareness activities help to enhance the perception, diagnosis, and management of Fabry disease, which is thereby expected to drive market growth over the study period.
In addition, the rise in research and development and increase in funding related to Fabry disease treatment is also expected to fuel the market growth. For instance, in December 2022, Bio Sidus SA sponsored a clinical trial to evaluate the efficacy and safety of AGA BETA BS in patients with FD already treated and previously stabilized with Fabrazyme. Also, various Fabry disease pipeline products that have the potential to receive regulatory approvals also drive the growth of the market. For instance, in August 2021, the European Commission approved Galafold, marketed by Amicus Therapeutics, for the long-term treatment of Fabry disease patients aged 12 years and above with an amenable mutation.
Thus, owing to the increased awareness of FD, the rise in product launches, and regulatory approval for FD therapies, the studied market is expected to witness significant growth over the study period. However, the lack of diagnostic resources in emerging countries will impede market growth over the study period.
